KCHO-1, a Novel Antineuroinflammatory Agent, Inhibits Lipopolysaccharide-Induced Neuroinflammatory Responses through Nrf2-Mediated Heme Oxygenase-1 Expression in Mouse BV2 Microglia Cells

Figure 4

The effects of KCHO-1 on NF-κB activation (a), IκB-α phosphorylation, degradation of IκB-α (b), and NF-κB DNA binding activity (c) in BV2 microglia. The cells were pretreated for 12 h with the indicated concentrations of KCHO-1 and stimulated for 1 h with LPS (1 μg/mL). Western blot analysis of IκB-α and p-IκB-α in the cytoplasm and NF-κB in the nucleus (a, b) was performed as described in the Materials and Methods. A commercially available NF-κB enzyme-linked immunosorbent assay (ELISA) kit (Active Motif) was used to test nuclear extracts and determine the degree of NF-κB binding (c). The data represent the mean values from 3 experiments ± SD. compared with the LPS-treated group.

(a)

(b)

(c)